PMID- 16979120
OWN - NLM
STAT- MEDLINE
DCOM- 20061213
LR  - 20181113
IS  - 1567-5769 (Print)
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 6
IP  - 11
DP  - 2006 Nov
TI  - Changes in maternal and fetal nicotine distribution after maternal administration 
      of monoclonal nicotine-specific antibody to rats.
PG  - 1665-72
AB  - Vaccination against nicotine to elicit the production of nicotine-specific 
      antibodies is a potential treatment for tobacco addiction which reduces nicotine 
      distribution from serum to brain. Vaccination of pregnant rats also reduces the 
      distribution of maternally-administered nicotine to the fetal brain. Whether this 
      is due to maternal antibody reducing the transfer of nicotine from mother to 
      fetus, or to fetal antibody altering the distribution of nicotine within the 
      fetus, is not clear. In the current study, passive immunization of rats with the 
      murine monoclonal nicotine-specific antibody Nic311 was used as a surrogate for 
      vaccination because antibody transfer to the fetus was anticipated to be lower 
      than with vaccination. Pregnant rats received nicotine from gestational day (GD) 
      18-20 as frequent i.v. boluses to simulate nicotine exposure from smoking. Nic311 
      was administered at doses of 30, 80 or 240 mg/kg on GD 19. Fetal serum Nic311 
      levels on GD 20 were <3% of concurrent maternal levels, but concentrations of up 
      to 20 ug/ml in fetal serum were obtained owing to the very high levels in 
      maternal serum. Accumulation of the chronically administered nicotine, measured 
      on GD 20, was not changed by Nic311 treatment in either maternal or fetal brain. 
      The early distribution of nicotine to maternal brain, measured 5 min after a 
      dose, was markedly reduced by Nic311, while the early distribution of nicotine to 
      whole fetus and fetal brain was not substantially altered. These data suggest 
      that the limited transfer of Nic311 to the fetus in turn limits the ability of 
      Nic311 to reduce nicotine distribution to the fetal brain.
FAU - Keyler, D E
AU  - Keyler DE
AD  - College of Pharmacy, University of Minnesota Minneapolis, MN, United States; 
      Minneapolis Medical Research Foundation, Minneapolis, MN, United States.
FAU - Lesage, M G
AU  - Lesage MG
FAU - Dufek, M B
AU  - Dufek MB
FAU - Pentel, P R
AU  - Pentel PR
LA  - eng
GR  - 5442RR005991-15/RR/NCRR NIH HHS/United States
GR  - R01 DA015668/DA/NIDA NIH HHS/United States
GR  - T32 DA007097/DA/NIDA NIH HHS/United States
GR  - U42 RR005991/RR/NCRR NIH HHS/United States
GR  - DA10714/DA/NIDA NIH HHS/United States
GR  - DA015668/DA/NIDA NIH HHS/United States
GR  - T32-DA07097/DA/NIDA NIH HHS/United States
GR  - R01 DA010714/DA/NIDA NIH HHS/United States
GR  - R01 DA010714-12/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060804
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antibodies, Monoclonal)
RN  - 6M3C89ZY6R (Nicotine)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacokinetics/*pharmacology
MH  - Brain/metabolism
MH  - Female
MH  - *Immunization, Passive
MH  - Maternal-Fetal Exchange
MH  - Mice
MH  - Nicotine/blood/*immunology/*pharmacokinetics
MH  - Pregnancy
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC2727278
MID - NIHMS20734
EDAT- 2006/09/19 09:00
MHDA- 2006/12/14 09:00
PMCR- 2009/08/14
CRDT- 2006/09/19 09:00
PHST- 2006/06/26 00:00 [received]
PHST- 2006/06/30 00:00 [accepted]
PHST- 2006/09/19 09:00 [pubmed]
PHST- 2006/12/14 09:00 [medline]
PHST- 2006/09/19 09:00 [entrez]
PHST- 2009/08/14 00:00 [pmc-release]
AID - S1567-5769(06)00200-1 [pii]
AID - 10.1016/j.intimp.2006.06.013 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2006 Nov;6(11):1665-72. doi: 10.1016/j.intimp.2006.06.013. 
      Epub 2006 Aug 4.